ZA200203985B - Therapies for tissue damage resulting from ischemia. - Google Patents

Therapies for tissue damage resulting from ischemia.

Info

Publication number
ZA200203985B
ZA200203985B ZA200203985A ZA200203985A ZA200203985B ZA 200203985 B ZA200203985 B ZA 200203985B ZA 200203985 A ZA200203985 A ZA 200203985A ZA 200203985 A ZA200203985 A ZA 200203985A ZA 200203985 B ZA200203985 B ZA 200203985B
Authority
ZA
South Africa
Prior art keywords
ischemia
tissue damage
therapies
damage resulting
resulting
Prior art date
Application number
ZA200203985A
Other languages
English (en)
Inventor
Banavara L Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200203985B publication Critical patent/ZA200203985B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200203985A 2001-05-24 2002-05-20 Therapies for tissue damage resulting from ischemia. ZA200203985B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29339301P 2001-05-24 2001-05-24

Publications (1)

Publication Number Publication Date
ZA200203985B true ZA200203985B (en) 2003-11-20

Family

ID=23128899

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203985A ZA200203985B (en) 2001-05-24 2002-05-20 Therapies for tissue damage resulting from ischemia.

Country Status (15)

Country Link
US (1) US6872722B2 (https=)
EP (1) EP1260224B1 (https=)
JP (1) JP2002370984A (https=)
KR (1) KR20020090321A (https=)
CN (1) CN1390547A (https=)
AT (1) ATE289510T1 (https=)
AU (1) AU761191B2 (https=)
CA (1) CA2387007A1 (https=)
CZ (1) CZ20021782A3 (https=)
DE (1) DE60203026T2 (https=)
ES (1) ES2236447T3 (https=)
HU (1) HUP0201738A3 (https=)
PL (1) PL354128A1 (https=)
SK (1) SK7332002A3 (https=)
ZA (1) ZA200203985B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DK1961420T3 (da) * 2005-12-16 2012-08-27 Sanwa Kagaku Kenkyusho Co Middel til forebyggelse og behandling af akut nyresvigt
KR20080108465A (ko) * 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH01258671A (ja) * 1987-12-01 1989-10-16 Morishita Pharmaceut Co Ltd 5−(1h−イミダゾール−1−イル)−3(2h)−ピリダジノン誘導体
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
WO1992017446A2 (en) * 1991-03-28 1992-10-15 Pfizer Inc. Pyridazinone acetic acids aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
CN1142148C (zh) * 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−3−オン誘導体及びこれを含有する医薬
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors

Also Published As

Publication number Publication date
US6872722B2 (en) 2005-03-29
AU761191B2 (en) 2003-05-29
EP1260224B1 (en) 2005-02-23
JP2002370984A (ja) 2002-12-24
DE60203026D1 (de) 2005-03-31
CN1390547A (zh) 2003-01-15
CZ20021782A3 (cs) 2003-03-12
EP1260224A1 (en) 2002-11-27
HUP0201738A2 (hu) 2003-02-28
ES2236447T3 (es) 2005-07-16
HUP0201738A3 (en) 2003-11-28
ATE289510T1 (de) 2005-03-15
US20030008871A1 (en) 2003-01-09
DE60203026T2 (de) 2006-05-04
PL354128A1 (en) 2002-12-02
KR20020090321A (ko) 2002-12-02
SK7332002A3 (en) 2003-05-02
AU4068502A (en) 2002-11-28
HU0201738D0 (https=) 2002-07-29
CA2387007A1 (en) 2002-11-24

Similar Documents

Publication Publication Date Title
GB0108592D0 (en) Therapeutic agents
BG108137A (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ZA200309808B (en) Compositions and methods for the diagnosis and treatment of tumor
GB0223040D0 (en) Therapeutic compounds
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
WO2006024018A3 (en) Compositions for treating nociceptive pain
PL1660057T3 (pl) Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
PL367198A1 (en) Antiangiogenic combination therapy for the treatment of cancer
EP1448205A4 (en) COMBINATIONS FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISEASES
IL159887A0 (en) Combination therapy for the treatment of cancer
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
WO2000021513A3 (en) Methods for treating multiple sclerosis
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
ZA200203985B (en) Therapies for tissue damage resulting from ischemia.
BG105953A (bg) Метод за лечение на хронична обструктивна белодробна болест
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
SI1606233T1 (sl) Fosfolipidni estri klofarabina
AU2001285156A1 (en) Combination therapy for the treatment of migraine
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
YU51802A (sh) Nova terapeutska primena enoksaparina
AU2003223184A1 (en) Methods of preventing or treating brain ischemia or brain injury